ENDV — Endonovo Therapeutics Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.00m
- $7.06m
- $0.14m
Brief: Endonovo’S Sofpulse® Nears Final Stages To Receive Taiwan FDA License To Distribute In Taiwan
Brief: Endonovo Therapeutics Inc - Sofpulse, Inc. Will Operate Independently After Planned Spin-Off
Brief: Endonovo Therapeutics Details Plan To Spin Off Medical Device Division As A Listed Public Company
Brief: Endonovo Announces Plan To Explore Strategic Alternatives For Its Sofpulse Medical Device Assets
Brief: Endonovo Therapeutics to acquire Rio Grande Neurosciences